• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Environmental Impact Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits (Amendment)

    1/7/22 4:15:26 PM ET
    $ENVI
    Get the next $ENVI alert in real time by email
    0001822691 true 0001822691 2021-01-19 2021-01-19 0001822691 ENVI:UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemableWarrantMember 2021-01-19 2021-01-19 0001822691 ENVI:ClassCommonStockParValue0.0001PerShareMember 2021-01-19 2021-01-19 0001822691 ENVI:WarrantsEachExercisableForOneShareClassCommonStockFor11.50PerShareMember 2021-01-19 2021-01-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K/A

    Amendment No. 1

     CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): January 19, 2021

     

    Environmental Impact Acquisition Corp.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39894   85-1914700
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    535 Madison Avenue
    New York, NY 10022 

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (212) 389-8109

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant   ENVIU   The Nasdaq Stock Market LLC
    Class A Common Stock, par value $0.0001 per share   ENVI   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one share Class A Common Stock for $11.50 per share   ENVIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Environmental Impact Acquisition Corp., (the “Company”) is filing this Amendment No. 1 to its Current Report on this Form 8-K/A for the Initial Public Offering date of January 19, 2021 (the “First Amendment”), as originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 25, 2021 (the “Original Form 8-K”) to amend and restate the Company’s audited balance sheet and accompanying footnotes as of January 19, 2021 on Form 8-K, as further described below.

     

    This amended and restated report on Form 8-K/A is presented as of the filing date of the Original Form 8-K and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatement as described below. Accordingly, this Amendment No. 1 on Form 8-K/A should be read in conjunction with our filings with the SEC subsequent to the date on which we filed the Original Form 8-K.

     

    The Company is filing this First Amendment on Form 8-K/A to reflect a restatement of the Company’s audited balance sheet as of January 19, 2021, to correct errors in the Company’s classification of public shares as permanent equity as well as to correct errors in the Company’s classification of warrants as liabilities as further described below.

     

    Background of Restatement

     

    All of the shares held by the Company’s public stockholders (the “Public Shares”) contain a redemption feature which provides each holder of such shares with the opportunity to have their shares redeemed, and management has no control over which Public Shares will be redeemed. ASC 480-10-S99-3A provides that redemption provisions not solely within the control of the issuer require shares subject to redemption to be classified outside of permanent equity. Furthermore, ASC 480-10-25-6(b) provides guidance stating that in determining if an instrument is mandatorily redeemable, a provision that defers redemption until a specified liquidity level is reached would not affect classification of the instrument. As such, management has identified errors made in the historical financial statements where, at the closing of the Company’s initial public offering (“Initial Public Offering”), the Company improperly valued its Class A common stock subject to possible redemption. The Company previously determined the Class A common stock subject to possible redemption to be equal to the redemption value, while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Management determined that the Public Shares can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control. Therefore, management concluded that the redemption value should include all Class A common stock subject to possible redemption, resulting in the Class A common stock subject to possible redemption being equal to their redemption value. As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity as of the Initial Public Offering date and all subsequent reporting periods.

     

    As a result, the Company’s management, together with the Audit Committee, determined that the Company’s financial statements and other financial data as of January 19, 2021 (the Initial Public Offering date) should be restated. This restatement results in a change in the initial carrying value of the Class A common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and Class A common stock. Further, there is no impact to the reported amounts for total assets related to this restatement.

     

    The Company previously accounted for its outstanding Public Warrants (as defined in Note 9) and Private Placement Warrants (collectively, with the Public Warrants, the “Warrants”) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities.

     

    1

     

     

    On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement (the “Warrant Agreement”).

     

    In further consideration of the SEC Statement, the Company’s management further evaluated the Warrants under Accounting Standards Codification (“ASC”) Subtopic 815-40, Contracts in Entity’s Own Equity. ASC Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer’s common stock. Under ASC Section 815-40-15, a warrant is not indexed to the issuer’s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management’s evaluation, the Company’s audit committee, in consultation with management, concluded that the Company’s Private Placement Warrants are not indexed to the Company’s common stock in the manner contemplated by ASC Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. In addition, based on management’s evaluation, the Company’s audit committee, in consultation with management, concluded that the tender offer provision fails the “classified in stockholders’ equity” criteria as contemplated by ASC Section 815-40-25.

     

    As a result of the above, the Company should have classified the Warrants as derivative liabilities in its previously issued financial statement as of January 19, 2021. Under this accounting treatment, the Company is required to measure the fair value of the Warrants at the end of each reporting period as well as re-evaluate the treatment of the Warrants and recognize changes in the fair value from the prior period in the Company’s operating results for the current period.

     

    The financial information that has been previously filed or otherwise reported for this period is superseded by the information in this First Amendment, and the financial statement and related financial information contained in the January 19, 2021 IPO 8-K should no longer be relied upon. On November 24, 2021, the Company filed a Current Report on Form 8-K disclosing the non-reliance on the financial statement included in the Original Form 8-K.

     

    The following items have been amended as a result of the restatement:

     

    Exhibit No.99.1, “Audited Balance Sheet as of January 19, 2021”

     

    In accordance with applicable SEC rules, this First Amendment on Form 8-K/A includes an updated signature page.

     

    Refer to Note 2, Restatement of Previously Issued Financial Statement of this Form 8-K/A for additional information and for the summary of the accounting impacts of these adjustments to the Company’s balance sheet as of January 19, 2021.

     

    The Company identified a material weakness in internal controls related to the accounting for complex financial instruments issued in connection with our initial public offering. As a result of the restatement described in this First Amendment on Form 8-K/A, the Company has concluded there was a material weakness in the Company’s internal control over financial reporting at the time the abovementioned financial statement was issued, and its disclosure controls and procedures were not effective at the time the abovementioned financial statement was issued.

     

    2

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On January 19, 2021, Environmental Impact Acquisition Corp., a Delaware corporation (the “Company”), consummated its initial public offering (the “IPO”) of 20,700,000 units (the “Units”) including 2,700,000 Units issued to the underwriter’s upon full exercise of their over-allotment option. Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Class A Common Stock”), and one-half of one redeemable warrant of the Company (“Warrant”), with each whole Warrant entitling the holder thereof to purchase one share of Class A Common Stock for $11.50 per share. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $207,000,000.

     

    Simultaneously with the closing of the IPO, pursuant to a Private Placement Warrants Purchase Agreement by and between the Company and HB Strategies LLC, the Company completed the private sale of 2,000,000 warrants (the “Private Placement Warrants”) to HB Strategies LLC at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $2,000,000 (the “Private Placement”). The Private Placement Warrants are identical to the Warrants included in the Units sold as part of the Units in the IPO, except as otherwise disclosed in the Registration Statement. No underwriting discounts or commissions were paid with respect to such sale.

     

    A total of $207,000,000 comprised of $206,750,000 of the proceeds from the IPO and $250,000 of the proceeds of the sale of the Private Placement Warrants, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee.

     

    An audited balance sheet as of January 19, 2021 reflecting receipt of the proceeds upon consummation of the IPO, including full exercise of the underwriter’s over-allotment option, and the Private Placement has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are being filed herewith:

     

    Exhibit No.    Description
         
    99.1   Audited Balance Sheet as of January 19, 2021.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Environmental Impact Acquisition Corp.
         
      By: /s/ Daniel Coyne
        Name:  Daniel Coyne
        Title: Chief Executive Officer
         
    Dated: January 7, 2022    

     

     

    4

     

     

     

     

    Get the next $ENVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENVI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GreenLight Biosciences begins trading today as Nasdaq: GRNA on the closing of its business combination with Environmental Impact Acquisition Corp.

      BOSTON, Feb. 3, 2022 /PRNewswire/ -- GreenLight Biosciences ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) ("ENVI"), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination. In connection with the closing, the company changed its name to GreenLight Biosciences Holdings, public-benefit corporation, with shares of Class A common stock and public warrants

      2/3/22 10:02:00 AM ET
      $ENVI
    • Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nasdaq: GRNA on February 3, 2022

      BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ:ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination with Greenlight Biosciences was approved in a shareholder vote held yesterday, with 80.7% of shareholders participating in the vote and 78.6% voting in favor of the combination. Subject to the satisfaction or waiver of the other customary closing conditions, Environmental Impact Acquisition Corp. anticipates closing the business combination today. In connection with the closing, the

      2/2/22 8:58:00 AM ET
      $ENVI
    • GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World's First dsRNA Seed Treatment to Control Pests

      BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions. Through the partnership, the two companies will explore synergies between Germains' seed priming and coating technologies and GreenLight's dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops

      1/31/22 10:40:00 AM ET
      $ENVI

    $ENVI
    SEC Filings

    See more
    • SEC Form 425 filed by Environmental Impact Acquisition Corp.

      425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

      2/2/22 8:34:52 AM ET
      $ENVI
    • Environmental Impact Acquisition Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Environmental Impact Acquisition Corp (0001822691) (Filer)

      2/2/22 8:32:05 AM ET
      $ENVI
    • SEC Form 425 filed by Environmental Impact Acquisition Corp.

      425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

      1/28/22 9:10:59 AM ET
      $ENVI

    $ENVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Walker Matthew Alan was granted 14,343,021 shares and bought $15,000,000 worth of shares (1,500,000 units at $10.00)

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      2/4/22 8:22:17 PM ET
      $ENVI
    • SEC Form 3 filed by new insider Walker Matthew Alan

      3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      2/4/22 8:20:21 PM ET
      $ENVI
    • SEC Form 4 filed by Keefe Susan

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      2/4/22 8:01:51 PM ET
      $ENVI

    $ENVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board

      BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board. At Johns Hopkins University, Diane Griffin is the Distinguished Service Professor, a professor of Medicine and Neurology at the School of Medicine, and the W. Harry Feinstone professor at the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. She has also been vice president of the U.S. National Academy of Sciences since

      11/4/21 10:02:00 AM ET
      $ENVI
    • GreenLight Biosciences Announces the Appointment of Jennifer Raymond As SVP, CMC and Manufacturing

      BOSTON, Sept. 16, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the appointment of Jennifer Raymond as SVP, CMC & Manufacturing today. Raymond joins GreenLight from GSK with more than 23 years of experience in the pharmaceutical industry, including 13 years in vaccines development, production, and Quality Assurance, across Merck, Novartis, and GSK. She has comprehensive first-hand experience in both R&D and Operations in small and large scale biological platforms (mammalian, viral, bacterial). Raymond's recent work includes development and launch of specialty biophar

      9/16/21 12:02:00 PM ET
      $ENVI

    $ENVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Environmental Impact Acquisition Corp.

      SC 13G - Environmental Impact Acquisition Corp (0001822691) (Subject)

      7/6/21 5:19:57 PM ET
      $ENVI